Journal Article10.1021/CG025559K
Process Optimization of a Complex Pharmaceutical Polymorphic System via In Situ Raman Spectroscopy
Cindy Starbuck,Angela Spartalis,Lawrence Wai,Jian Wang,Paul Fernandez,Christopher M. Lindemann,George Zhou,Zhihong Ge +7 more
106
TL;DR: In situ Raman spectroscopy was used to determine the rate of polymorph turnover for MK-A, a multipolymorphic compound in development at Merck Research Laboratories as discussed by the authors.
read more
Abstract: In situ Raman spectroscopy was used to determine the rate of polymorph turnover for MK-A, a multipolymorphic compound in development at Merck Research Laboratories. The known crystal forms of MK-A include four anhydrous polymorphs, two hydrates, and numerous solvates. The penultimate and pure steps of this process involve a coupling reaction to generate a mixture of crystal forms followed by turnover to the desired polymorph, form A. This paper summarizes experiments to measure the kinetics of polymorph turnover from all relevant MK-A crystal forms to form A. Additionally, the turnover kinetics for polymorph reversion from form A to undesired forms were measured under simulated process upset conditions. The use of thermodynamic data to establish process boundaries and kinetic data to establish process time cycles resulted in the definition of a highly robust, cycle time efficient slurry turnover process to produce form A from any combination of other MK-A crystal forms.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
First-principles and direct design approaches for the control of pharmaceutical crystallization
TL;DR: In this article, the authors provide an overview of recent technological advances in the in situ control of pharmaceutical crystallization processes, and their relative merits are explained, as well as areas of future opportunities for application of advanced control strategies.
359
Applications of process analytical technology to crystallization processes.
TL;DR: The concept of PAT is introduced and its application to crystallization processes is discussed through review of several case studies and a variety of in situ analytical methods combined with chemometric tools for analysis of multivariate process information provide a basis for future improvements in modeling, simulation, and control of crystallization methods.
330
Polymorphism in Processes of Crystallization in Solution: A Practical Review
TL;DR: In this article, the authors review the polymorphism of organic molecules obtained through batch crystallization in solution carried out in a stirred vessel, and discuss the advantages and drawbacks of using process analytical technologies to monitor such transitions.
187
In situ raman spectroscopy for in-line control of pharmaceutical crystallization and solids elaboration processes: A review
Gilles Févotte,Gilles Févotte +1 more
TL;DR: In this article, the main potential applications of the technique, its advantages and drawbacks, and studies reporting on the real-time use of Raman spectroscopy for monitoring solid pharmaceutical elaboration processes are presented.
144
Recent Advances in Crystallization control: An Industrial Perspective
TL;DR: In this paper, the authors review the important recent developments in the control of crystallization process, and discuss their feasibility and scope for implementation in industrial processes, including particle size distribution (PSD), crystal habit and polymorphic form.
143
References
Pharmaceutical Solids: A Strategic Approach to Regulatory Considerations
TL;DR: It is hoped that this review will lead to a more direct approach to the characterization of pharmaceuticalsolids and ultimately to faster approval of regulatory documents containing information on pharmaceutical solids.
992
Dealing with the Impact of Ritonavir Polymorphs on the Late Stages of Bulk Drug Process Development
Sanjay R. Chemburkar,Bauer John F,Kris C. Deming,Harry O. Spiwek,Patel Ketan M,John Morris,Rodger F. Henry,Stephen G. Spanton,Walter Dziki,William Porter,John Quick,Phil Bauer,John Donaubauer,B. A. Narayanan,Mauro Soldani,and Dave Riley,Kathyrn McFarland +16 more
TL;DR: From the discovery of ritonavir until the new drug application (NDA) filing, only one crystalline form was known to exist, and this new crystal form was designated as Form II.
683